Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Toni Wheeler who wrote (2740)	11/8/1999 1:33:00 PM
From: ccryder	Respond to of 2836

I read a little more into this than what was stated. Previous therapy was to inject Multikine (TM) into a site opposite from the tumor. Now it appears that the treatment is more aggressive not only in dose but in site. I take this to mean that Multikine is being given an increased chance to work even though the total duration is still only two weeks. The bold type in the second paragraph is also indicative to me of a more aggressive campaign to elicit a change in the two week protocol to a longer time period. We were also promised the long term survival results from those people in the study in Israel when the papers have received their peer review and are published. That the company has made this promise at all says to me that the results must be very encouraging indeed. It is my understanding that even when the "conventional therapies" are considered successful, long term survivability is measured in months, not years.